36166-75-3

Usage

Uses

Used in Pharmaceutical Industry:
1,2,3,6-tetrahydro-1-methylpyridine-4-methanol is used as a precursor in organic synthesis for the production of pharmaceuticals. Its multifunctional nature allows for the creation of a variety of different compounds, making it a valuable asset in drug development.
Used in Medicinal Chemistry Research:
THM-4 is used as a building block in medicinal chemistry for the design and synthesis of novel therapeutic agents. Its antioxidant properties and potential applications in treating neurological disorders make it a promising candidate for further research and development.
Used in Antioxidant Formulations:
1,2,3,6-tetrahydro-1-methylpyridine-4-methanol is used as an antioxidant in various formulations. Its ability to neutralize free radicals and protect cells from oxidative damage makes it a valuable component in health supplements and skincare products.
Used in Neurodegenerative Disease Treatment:
THM-4 is being investigated for its potential use in treating neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease. Its neuroprotective properties and ability to modulate cellular pathways involved in these disorders make it a promising therapeutic agent for further exploration.

InChI:InChI=1/C7H13NO/c1-8-4-2-7(6-9)3-5-8/h2,9H,3-6H2,1H3

Upstream product

• 40175-06-2 ethyl 1-methyl-1,2,5,6-tetrahydropyridine-4-carboxylate 
• 10129-59-6 1-methyl-4-ethoxycarbonylpyridinium iodide 
• 74-88-4 methyl iodide 
• 586-95-8 pyridine-4-methanol 

Downstream Products

• 1219-99-4 N,N'-bis(4-chlorophenyl)urea 
• 13208-31-6 N_.N'-Di-(m-chlor-phenyl)-harnstoff 
• 102397-54-6 (3-Chloro-phenyl)-carbamic acid 1-methyl-1,2,3,6-tetrahydro-pyridin-4-ylmethyl ester 
• 179064-39-2 4-<(2-iodophenoxy)methyl>-1-methyl-1,2,3,6-tetrahydropyridine 
• 20691-89-8 1-methyl-4-piperidinemethanol 
• 180083-23-2 1'-methyl-5-([2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl)-2,3,6,7-tetrahydro-spiro(furo[2,3-f]indole-3,4'-piperidine) 

Relevant academic research and scientific papers

Indazole derivatives having monocyclic amine

An indazole compound having the formula (I): wherein: R1 is hydrogen, C1 -C6 alkyl, C3 -C6 alkenyl or C3 -C6 cycloalkyl; Q is carbonyl, thiocarbonyl or methylene; and R2 is a group of the formula (II) or (IV); STR1 wherein R1 is C1 -C6 alkyl, C3 -C6 alkenyl or benzyl, of which a phenyl group thereof is optionally mono- or di-substituted by the same or different halogen or methoxy; m is 0 to 2; n and o is 1 or 2. The compound exhibits 5-HT4 receptor agonist activity.

Synthesis, pharmacology, and molecular modeling studies of semirigid, nicotinic agonists

Eight nicotinic agonists were synthesized, and their potencies were estimated by contracture of the frog rectus abdominis muscle. The most potent, 1-methyl-4-acetyl-1,2,3,6-tetrahydropyridine methiodide (3b), 50 times as potent as carbamylcholine, served as a template for the rest. Although all of the agonists could easily conform to the putative nicotinic pharmacophore, their potencies spanned a nearly 10,000-fold range. This pharmacophore, therefore, may be necessary but deficient. Computer-assisted molecular modeling studies helped to delineate additional factors that may contribute to potency. The factors are (1) the ground-state conformation, (2) superimposability of the hydrogen bond acceptor and the cationic head onto the template, (3) electrostatic potential at the cationic head and at the hydrogen bond acceptor site, and (4) the presence of a methyl group bonded to the carbon atom that bears the hydrogen bond acceptor. A new program, ARCHEM, was used to calculate and to visualize electrostatic potentials at the van der Waals surfaces of the agonists.